Distribution of stable isotope values for consumers faceted by coastscape and feeding habit. حسب Nathan D. McTigue (10706460)

Distribution of stable carbon and nitrogen values for pPOM and sPOM. حسب Nathan D. McTigue (10706460)

Niche overlap within shelf communities. حسب Nathan D. McTigue (10706460)

Niche overlap within fjord communities. حسب Nathan D. McTigue (10706460)

Sampling locations across the Arctic where data were aggregated. حسب Nathan D. McTigue (10706460)

Heuristics developed to identify coastscapes in the coastal Arctic habitat continuum. حسب Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap for feeding habits between coastscapes. حسب Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap in shelves. حسب Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap in fjords. حسب Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for predators. حسب Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for deposit feeders. حسب Nathan D. McTigue (10706460)

Mathematical treatments applied to data to correct stable isotope values for lipid content. حسب Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for suspension feeders. حسب Nathan D. McTigue (10706460)

Histogram of day-of-year for sample collection for data collected for this meta-analysis. حسب Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for opportunist/scavengers. حسب Nathan D. McTigue (10706460)

Stable isotope biplots of end-members (colored points) faceted by coastscape and overlayed consumers (gray points). حسب Nathan D. McTigue (10706460)

Summary statistics of δ¹³C and δ¹⁵N for end-members and consumer feeding habits. حسب Nathan D. McTigue (10706460)

Results from linear regression analysis for δ¹³C or δ¹⁵N and collection date. حسب Nathan D. McTigue (10706460)

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. حسب Masashi Okawa (8951294)

"…<b>c</b> Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, <i>p</i> = 0.7096 vs control; +20 μg/mL, <i>p</i> = 0.0107 vs control; +200 μg/mL, <i>p</i> < 0.0001 vs control). …"

CRISPRi interrogation of the <i>Sox10</i> ECs. حسب Hongjoo An (21703199)